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Abstract
Trends in transmitted drug resistance-associated mutations (TDRM) in HIV-1infection vary depending on
geographic and cohort characteristics. The impact of TDRM among patients receiving fully active combination
antiretroviral therapy (cART) is poorly characterized. This was a retrospective study of 801 HIV-1-infected
treatment-naive patients from 2001 to 2009 who had pre-cART genotype resistance test results available. The
prevalence of TDRM was compared for each year strata. Multivariate Cox proportional hazards regression
models were used to assess factors associated with virologic failure at 48 weeks. TDRM was detected in 136
(17%) patients with ‡ 2 class TDRM in 20 patients. K103N/S was the most frequent (n = 77). There were no
changes in the prevalence of mutations over time (Ptrend = 0.67). Six hundred and eleven patients were started on
cART. Virologic failure occurred in 38% of those with TDRM and 24% of those without ( p < 0.01). In multivariate
analysis, nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance was associated with a 1.5-fold in-
creased risk of virologic failure. TDRM remains common among treatment-naive HIV-1-infected patients, af-
fecting one in six patients. Transmission of NNRTI drug resistance was associated with risk of virologic failure
despite initiation of genotype-guided cART.
Introduction
The use of potent combination antiretroviral therapy(cART) provides sustained virologic suppression for an
individual living with HIV and substantially reducing the
morbidity and mortality associated with HIV-1 infection.1
Despite this advance in treatment, virologic failure can develop
in 10–20% as a result of suboptimal medication adherence, the
presence of preexisting drug resistance, or the emergence of
drug resistance.2,3 Transmitted drug resistance-associated
mutations (TDRM) are of particular concern as they limit the
choice of first-line cART, decrease efficacy of subsequent anti-
retroviral regimens and increase the risk of treatment failure.4–6
TDRM have been documented among treatment-naive HIV-1-
infected patients with a prevalence ranging from 3% to 24%,
depending on the cohort and geographic characteristics; the
highest prevalence is noted in countries with long-established
use of antiretrovirals.7–11 Studies on time trends in the preva-
lence of TDRM are inconsistent. In Belgium, the overall prev-
alence of TDRM was reported at 8.4% with no time trend.12
Bracciale et al. demonstrated that the transmission of nucleo-
side reverse transcriptase inhibitor (NRTI) and protease in-
hibitor (PI) resistance declined over time, but nonnucleoside
reverse transcriptase inhibitor (NNRTI) resistance increased
from 3.7% during 1996–2001 to 7.8% during 2002–2004 and
remained stable thereafter (5.8% in 2006–2007).13
Previous data highlight that the presence of TDRM influ-
ences the outcome of initial cART and pre-cART genotype
resistance testing improves clinical outcomes and is cost ef-
fective.14,15 Therefore, routine genotype resistance testing is
considered the standard of care for all newly diagnosed HIV-
1-infected patients to guide the choice of initial treatment.16
Yet there are few studies evaluating the impact of TDRM on
virologic efficacy when patients initiate cART with at least
three active agents chosen based on genotype resistance
testing. We evaluated the prevalence and time trend of TDRM
in a midwestern HIV outpatient clinic and the virologic out-
comes of treatment-naive patients who were started on cART
with at least three fully active agents guided by the result of
genotype resistance testing.
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All adult (age ‡ 18 years), treatment-naive HIV-1-infected
patients who were new to Washington University HIV Out-
patient Clinic from January 1, 2001 to June 30, 2009 were
screened for the study. Patients with HIV-1 genotype resis-
tance testing performed prior to starting on cART were in-
cluded in the study. This study was approved by the
Washington University School of Medicine Human Research
Protection Office.
The following data were abstracted from electronic medical
record: baseline demographics (age, sex, race, and HIV risk
factors), psychiatric comorbidity, substance use (history of
marijuana, cocaine, heroin, or methamphetamine use), to-
bacco use, sexually transmitted diseases (STDs: history of
syphilis, gonorrhea, Chlamydia trachomatis infection, or genital
herpes simplex virus infection), hepatitis C virus (HCV) co-
infection (positive anti-HCV antibody), longitudinal CD4 cell
counts, longitudinal HIV RNA levels, pre-cART HIV-1 ge-
notype, antiretroviral regimen, pre-cART opportunistic in-
fections, and the first date of virologic suppression on the
cART initiated. The definition of cART was receipt of at least
three active antiretroviral medications as part of a regimen.
The prevalence and trends of TDRM during the study pe-
riod were calculated. Genotypic assays were obtained from
either Quest Diagnostics or the Washington University Ret-
rovirus Laboratory (ViroSeq HIV-1 Genotyping System, Cel-
era Corporation, Alameda, CA). The genotype results were
interpreted with the standardized list of mutations for sur-
veillance of transmitted drug resistance (DRM) established by
the World Health organization (WHO list).17 TDRM were
noted individually and also grouped by antiretroviral class:
NRTI, NNRTI, and PI resistance mutations. To assess the
impact of TDRM, two groups (those with TDRM and those
without) were compared in regards to virologic outcomes
after initiating cART. Virologic suppression was defined as
HIV RNA level <400 copies/ml at 48 weeks. This cutoff was
used because some data predated the use of ultrasensitive
HIV RNA assays.
Statistical analysis
Differences between the groups were compared using chi-
square and Fisher exact test for categorical data and Mann–
Whitney tests for continuous variables. HIV RNA levels were
log10 transformed. Calculations of TDRM prevalence in each
antiretroviral class were conducted by using the number of
new cases of resistance detected in each year divided by the
number of new antiretroviral-naive patients in each year.
Time trends of prevalence in TDRM for each antiretroviral
class were analyzed by logistic regression. To assess the vi-
rologic outcomes, univariate analyses with a Cox propor-
tional hazards regression models with one predictor was
conducted. Patients were censored as virologic failure when
they did not achieve virologic suppression at 48 weeks.
Variables associated with virologic failure at p < 0.10 in the
univariate analyses were considered in the multivariate Cox
proportional hazards regression models. All statistical calcu-
lations were performed using R 2.12.0 (R Foundation for
Statistical Computing, Vienna, Austria), and statistical sig-
nificance was defined as p < 0.05.
Results
Among the 801 patients who had pre-cART genotype re-
sistance testing, 68% were male, 72% were black, and 35% had
a CD4 cell count <200 cells/mm3 (Table 1). Based on the
WHO list, TDRM was detected in 136 (17%) patients; NRTI
Table 1. Baseline Characteristics of the Study Population
All patients TDRM present No TDRM present
(N = 801) (N = 136) (N = 665) p value
Age, years (median, IQR) 31 24–41 29 22–39 32 24–41 <0.05
Male sex 545 68% 82 60% 462 79% <0.05
Race
Black 575 72% 99 73% 476 72% 0.96
White 201 25% 33 24% 168 25%
HIV risk factors
Heterosexual 356 44% 70 51% 286 43% 0.45
MSM 346 43% 51 38% 295 44%
IDU 29 4% 5 4% 24 4%
Psychiatric comorbidity 262 33% 45 33% 217 33% 0.99
Substance usea 336 42% 60 47% 276 44% 0.64
Tobacco use 439 55% 77 62% 362 58% 0.47
STDs 299 37% 58 43% 241 36% 0.19
HCV 61 8% 12 9% 49 7% 0.69
CD4 cell countb (median, IQR) 308 99–467 328 109–505 299 98–463 0.32
CD4 cell countb £200 cells/mm3 277 35% 42 31% 235 35% 0.37
log10 HIV RNA
b (median, IQR) 4.62 4.00–5.07 4.56 3.90–5.00 4.63 4.02–5.09 0.23
Initiated cART 611 76% 110 81% 501 75% 0.20
aSubstance abuse, history of marijuana, cocaine, heroin, or methamphetamine use.
bBaseline CD4 cell count and HIV RNA level.
TDRM, transmitted drug-resistant mutation; IQR, interquartile range; MSM, men who have sex with men; IDU, injection drug use; STDs,
sexually transmitted diseases within 1 year of initiating cART; HCV, chronic hepatitis C virus infection; cART, combination antiretroviral
therapy; CD4 cell count, CD4 cell count (cells/mm3); log10 HIV RNA, log10 HIV RNA plasma level (copies/ml).
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resistance was identified in 6% (n= 48), NNRTI resistance in
12% (n = 94), and PI resistance mutation in 2% (n= 18). Mu-
tations at T215 (n= 23, 2.9%) and M41 (n = 13, 1.6%) were the
two most commonly found NRTI resistance and K103N/S
(n = 77, 9.6%) was the most commonly found NNRTI resis-
tance, comprising almost half of the entire prevalence of
TDRM. L90M (n = 8, 1%), V82A/L (n= 8, 1%), and M46I/L
(n = 7, 0.9%) were the three commonly found PI resistance
mutations (Table 2). Among the 136 patients with TDRM, 20
(15%) patients had ‡ 2 class TDRM. There were no significant
time trends in the prevalence of any specific TDRM (Ptrend =
0.67), NRTI (Ptrend = 0.75), NNRTI (Ptrend = 0.99), and PI re-
sistance (Ptrend = 0.76) (Fig. 1).
Patients with TDRM and those without were compared.
Those with TDRM were younger and less likely male (both
p < 0.05), but other characteristics, race, and HIV risk factors
were similar. There were no differences in proportion of
patients with psychiatric comorbidities, substance use, to-
bacco use, or those with a history of STDs. Baseline CD4 cell
counts and HIV RNA levels did not differ between the
groups (Table 1).
Among the 801 treatment-naive patients with genotype
resistance testing, 611 patients (76%) were started on cART.
Pre-cART CD4 cell count and HIV RNA level did not differ
between the two groups. Patients with TDRM were started
more frequently on PI-based cART regimen ( p < 0.001). Vir-
ologic failure was observed in 42 (38%) of patients in the
TDRM group and 121 (24%) in those without ( p < 0.01).
Changes in CD4 cell count at 24 weeks (median increase of 136
Table 2. Frequency of Individual Resistance Mutations
2001–2003 2004–2006 2007–2009
Total
Drug class Mutation (N= 188) (N = 301) (N = 312) (N= 801) %
NRTI M184 (V/I) 1 3 0 4 0.5
M41L 1 7 5 13 1.6
D67 (N/E/G) 3 2 4 9 1.1
K70R 2 0 0 2 0.5
L210W 0 2 0 2 0.5
T215 (C/D/E/F/I/S/Y) 5 9 9 23 2.9
K219 (E/Q/R) 2 4 3 9 1.1
K65R 1 0 0 1 0.1
Y115F 0 1 0 1 0.1
T69D 0 2 3 5 0.6
Q151M 0 1 0 1 0.1
F77L 0 1 0 1 0.1
NNRTI L100I 1 2 2 5 0.6
K101E 0 1 1 12 1.5
K103 (N/S) 16 27 34 77 9.6
V106A 1 0 0 1 0.1
Y181C 2 4 2 8 1.0
Y188L 0 3 1 4 0.5
G190 (A/S) 4 3 2 9 1.1
P225H 0 1 3 4 0.5
PI M46 (I/L) 1 2 4 7 0.9
I50L 0 1 0 1 0.1
I54 (T/V) 1 3 1 5 0.6
G73S 0 0 1 1 0.1
V82 (A/L) 1 5 2 8 1.0
L90M 1 5 2 8 1.0
Drug resistance mutation based on the WHO list as described in the Materials and Methods section.
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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FIG. 1. Prevalence and trends of TDRM per year strata.
TDRM, transmitted drug-resistant mutation; NRTI, nucleo-
side reverse transcriptase inhibitor; NNRTI, nonnucleoside
reverse transcriptase inhibitor; PI, protease inhibitor.
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and 121 cell/mm3, p = 0.85) and 48 weeks (median increase of
159 and 156 cell/mm3, p = 0.78) did not differ between the two
groups (Table 3).
By univariate analyses, those with pre-cART opportunistic
infections (HR 0.68; 95% CI 0.56–0.84), the presence of any
TDRM (HR 0.70; 95% CI 0.54–0.91), the presence of NNRTI
resistance (HR 0.65; 95% CI 0.47–0.90), and plasma HIV RNA
level of greater than 100,000 copies/ml (HR 0.64; 95% CI 0.52–
0.78) were less likely to achieve virologic suppression at 48
weeks. Conversely, persons receiving a NNRTI -based regimen
rather than a PI-based regimen (HR 1.24; 95% CI 1.02–1.51) and
use of an efavirenz-based regimen rather than a boosted ata-
zanavir-based regimen (HR 1.31; 95% CI 1.02–1.68) were more
likely to achieve virologic suppression at 48 weeks.
The impact of NNRTI resistance on virologic outcomes was
analyzed by multivariate analyses, adjusting by the presence
of pre-cART opportunistic infections, a plasma HIV RNA le-
vel of greater than 100,000 copies/ml, and use of an NNRTI-
based regimen rather than PI-based regimen. NNRTI resis-
tance had HR of 0.67 (95% CI 0.47–0.94), conferring a 1.5-fold
increased risk of virologic failure (Table 4).
Discussion
In this cohort, the prevalence of TDRM was 17%, affecting
one in six newly diagnosed, treatment-naive HIV-infected
patients. Those with NNRTI resistance had a 1.5-fold in-
creased risk of virologic failure at 48 weeks. These data
highlight that TDRM, especially NNRTI resistance mutations,
have a meaningful negative impact on virologic outcomes
when HIV-infected treatment-naive patients initiate even
genotype guided cART.
Table 3. Bivariate Analyses of Patients Started on cART
All patients TDRM present No TDRM present
(N= 611) (N = 110) (N = 501) p value
Pre-cART CD4 cell count (median, IQR) 216 49–318 221 57–351 214 48–309 0.27
Pre-cART log10 HIV RNA (median, IQR) 4.75 4.20–5.30 4.72 4.23–5.00 4.78 4.19–5.34 0.17
Choice of cART
NNRTI + 2NRTI 353 58% 25 23% 328 66% <0.001
PI + 2NRTI 237 39% 80 73% 157 31% <0.001
Virologic failure at 48 weeks 163 27% 42 38% 121 24% <0.01
Changes in CD4 cell count (median, IQR)
At 24 weeks 124 60–205 136 55–194 121 61–211 0.85
At 48 weeks 156 86–269 159 70–292 156 88–265 0.78
cART, combination antiretroviral therapy; TDRM, transmitted drug-resistant mutation; IQR, interquartile range; pre-cART, prior to
initiation of cART; CD4 cell count, CD4 cell count (cells/mm3); log10 HIV RNA, log10 HIV RNA plasma level (copies/ml); NNRTI,
nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Table 4. Hazard Ratios for Achieving Virologic Suppression at 48 Weeks
by Univariate and Multivariate Analyses
Predictors Univariate HR (95% CI) p value Multivariate HR (95% CI) p value
Age group, years
>40 1.08 (0.88–1.33) 0.48
Sex
Male (ref. female) 0.99 (0.82–1.21) 0.99
Race
Black (ref. white) 1.02 (0.82–1.27) 0.85
Pre-cART opportunistic infections 0.68 (0.56–0.84) <0.001 0.76 (0.62–0.93) <0.01
Any TDRM 0.70 (0.54–0.91) <0.01
NRTI resistance 0.99 (0.69–1.43) 0.97
NNRTI resistance 0.65 (0.47–0.90) <0.01 0.67 (0.47–0.94) <0.01
PI resistance 1.22 (0.69–2.17) 0.49
Pre-cART CD4 cell count
£200 cells/mm3 0.88 (0.73–1.07) 0.19
Pre-cART HIV RNA level
>100,000 copies/ml 0.64 (0.52–0.78) <0.001 0.66 (0.54–0.80) <0.001
NNRTI-based regimen (ref. PI-based regimen) 1.24 (1.02–1.51) 0.03 1.18 (0.96–1.45) 0.12
EFV-based regimen (ref. ATV/r -based regimen) 1.31 (1.02–1.68) 0.03
Virologic suppression was defined as HIV RNA level <400 copies/ml at 48 weeks.
HR, hazard ratio; CI, confidence interval; TDRM, transmitted drug-resistant mutation; cART, combination antiretroviral therapy; pre-
cART, prior to initiation of cART; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; EFV, efavirenz; ATV/r, atazanavir boosted with ritonavir.
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Our findings can be explained by three possibilities. The
first is that NNRTI resistance mutations themselves confer a
higher risk for virologic failure. Second, NNRTI-based regi-
mens may simply be superior to PI-based regimens. In uni-
variate analyses, patients initiating an NNRTI-based regimen
were more likely to achieve virologic suppression at 48 weeks
when compared to those initiating a PI-based regimen. A
randomized clinical trial from the AIDS Clinical Trial Group
(ACTG) A5142 study similarly demonstrated the superiority of
an efavirenz-based regimen when compared to the PI-based
regimen using lopinavir/ritonavir.18 Conversely, other ran-
domized controlled studies such as the ACTG A5202 study or
the Altair study have demonstrated equivalent efficacy with
efavirenz- versus boosted atazanavir-based regimens.19,20
However, these studies excluded patients with known baseline
NNRTI resistance and thus cannot specifically address the is-
sue. A subanalysis of A5202 comparing the efficacy of efavir-
enz and boosted atazanavir between different males and
females showed the inferiority of boosted atazanavir in in black
race and females.21 The third possibility is that the presence of
NNRTI resistance may serve as a proxy for undetected drug
resistance mutations. Ultradeep sequencing may provide more
information about the presence of drug resistance mutations,
but this technique is available only in research settings and is
not clinically validated.22
The TDRM prevalence of 17% is comparable to the data
from the Centers for Disease Control and Prevention (16%
prevalence),23 and confirms the importance of monitoring for
TDRM. We were unable to confirm the decline in the preva-
lence of TDRM in our population over time despite the sim-
pler and potentially more potent cART regimen of the later
years. Factors that affect the prevalence of TDRM are not well
described and require further evaluation, particularly given
the relationship between TDRM and virologic outcomes and
the limited number of antiretroviral classes that are currently
available to treat HIV infection.
There are several limitations in our study. This was a ret-
rospective, single site study. We did not distinguish between
acute HIV infection and chronic HIV infection. Our results
potentially underestimate the prevalence of ‘‘nonfit’’ drug-
resistant mutations that will be difficult to detect after the
wild-type strains predominate. Nevertheless, the goal of our
study was to provide findings relevant to routine patient care
and genotypic testing is most commonly done in patients
presenting with established chronic HIV infection. Measure-
ment of virologic outcome was HIV RNA suppression at 48
weeks, which did not take into account subsequent virologic
failure. A previous study illustrated that short-term virologic
failure within 24 weeks may not translate to differences in
long-term clinical outcomes.24 Therefore, longitudinal data
should be collected for further analyses. Lastly, because this
was a retrospective review of data we did not have formal
measurements of cART adherence.
In summary, transmitted drug resistance mutations remain
prevalent in our community, affecting one in six newly di-
agnosed, treatment-naive HIV-infected patients. The presence
of TDRM negatively impacted virologic outcomes when
cART was initiated, especially when NNRTI resistance mu-
tations were present. Considering the significant effect of the
TDRM, its prevalence should be monitored and intervention
studies to lower the transmission of drug resistance should be
further developed.
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